The administration of broad-acting HDACis, such as vorinostat, meliorated intestinal inflammation by down-regulating inflammatory cytokines, including IFN-γ, in the CD4+ T cells of IBD model mice and suppressing their mobilization and accumulation [22,23]. Here, IFNG is linked to inflammatory bowel disease.